Lveffect 10 Tablet contains Dapagliflozin 10 mg, an oral antihyperglycemic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is primarily indicated for the management of type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise. Dapagliflozin works by inhibiting SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering plasma glucose levels. This mechanism is insulin-independent, making it effective across various stages of type 2 diabetes. In addition to glycemic control, Dapagliflozin has demonstrated benefits in reducing body weight and systolic blood pressure. It may also be prescribed for patients with heart failure with reduced ejection fraction and chronic kidney disease, as it has shown cardiovascular and renal protective effects. The recommended dose is typically 10 mg once daily, taken in the morning with or without food. Common adverse effects include urinary tract infections, genital mycotic infections, and increased urination. Caution is advised in patients with renal impairment, hypotension, or risk of ketoacidosis. Lveffect 10 Tablet should be used under medical supervision with regular monitoring of renal function and glycemic parameters to ensure safety and efficacy.